MAPLE SYRUP URINE DISEASE (MSUD)

disease center

Maple Syrup Urine Disease (MSUD) is a rare genetic disease that leads to a build up of the branchedchain amino acids (BCAAs) in the blood and urine.

Genetic mutations to one or more of the following genes prevents formation of a complex that is essential for breaking down the amino acids, leucine, isoleucine, and valine (the BCAAs):

-BCKDHA -BCKDHB -DBT both parents in one (or more) of three genes that produce proteins forming the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex (BC

MSUD is caused by

inherited mutations from

Signs and Symptoms include:



Neurological Damage BCAAs and their toxic by-products can build up in the blood and urine, so patients with MSUD are at constant risk of developing severe irreversible, neurological damage Example a constraint of the second se


Extremely high levels of BCAAs in the blood and urine can lead to urine with an odor similar to maple syrup

Current treatments have limitations

Monitoring and Diet Control:

MSUD patients must constantly monitor the chemistry of their blood and urine, and carefully control their diet for management of BCAA levels.

Liver Transplant Limited availability, high risk



POTENTIAL NEW THERAPIES FOR MSUD

Experimental, molecular therapies, including delivery of messenger RNA (mRNA) and AAV gene therapy strive to overcome the genetic mutation(s) causing MSUD in different ways.

1. 2. 3. 4. **Safety First** AAV vector is delivered a normal healthy copy Liver cells (hepatocytes) Functional proteins are produced and can break to the patient's body of the gene(s) containing take up vector and a mutation is produced through the circulatory begin to express down the BCAAs and prevent a toxic build up and is inserted into system with a one-time functional copies of the either a harmless viral intravenous injection affected gene of these amino acids and their by-products, vector lowering levels in the gene therapy has mRNA or gene proven releatively safe ntravenous blood injection and effective in animal models of MSUD What's next? Lipid nanoparticles are or a lipid nanoparticle containing an mRNA routinely administered via intravenous injection every few weeks **BCAAs** intra venous **BCAAs** injection Early clinical trials for MSUD evaluating safety in human subjects are next

